cobimetinib: Clinical Trials

112 trials of cobimetinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

54 completed, 19 terminated, 16 active not recruiting, 12 recruiting. 69 Phase 2, 45 Phase 1, 10 Phase 3, 2 Early Phase 1, 1 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 269Completed 27, Active not recruiting 12, Terminated 12, Recruiting 11, Unknown 4, Withdrawn 2, Suspended 1
Phase 145Completed 30, Terminated 9, Active not recruiting 4, Unknown 1, Withdrawn 1
Phase 310Completed 4, Active not recruiting 2, Recruiting 2, Terminated 1, Withdrawn 1
Early Phase 12Recruiting 1, Withdrawn 1
Not applicable1Terminated 1

Follow cobimetinib: new trials by email Literature Review of cobimetinib trials Research Report on cobimetinib

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma
Belvarafenib, Cobimetinib - Advanced or Metastatic Melanoma
Phase 2RecruitingHanmi Pharmaceutical Company Limited452026-02-122026-03-04
Using Tumor Models to Determine Treatments
Cobimetinib, Ponatinib, Brigatinib - Pancreatic Ductal Carcinoma, Advanced Cancer
Phase 2RecruitingUniversity Health Network, Toronto252025-04-072026-06-23
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
Biospecimen Collection, Cobimetinib, Computed Tomography - Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma
Phase 2RecruitingCity of Hope Medical Center212024-07-152026-02-02
T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma
T3011 + Cobimetinib - Melanoma, Malignant Melanoma
Phase 2SuspendedImmVira Pharma Co. Ltd682024-06-302024-02-01
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
Biopsy Procedure, Biospecimen Collection, Cobimetinib - Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma
Phase 1Active not recruitingNational Cancer Institute (NCI)422023-09-142026-10-09
Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Cobimetinib, Enasidenib Mesylate - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Phase 1CompletedCity of Hope Medical Center32023-04-282026-05-05
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
Alectinib, Atezolizumab, Entrectinib - Haematological Malignancy, Solid Tumour
Phase 2 / Phase 3RecruitingCancer Research UK8252023-03-012026-07-01
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Vemurafenib, Cobimetinib - Haematological Malignancy, Melanoma
Phase 2 / Phase 3RecruitingCancer Research UK302023-03-012025-11-24
SMMART Adaptive Clinical Treatment (ACT) Trial
Alectinib, Alpelisib, Anastrozole - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm
Early Phase 1WithdrawnOHSU Knight Cancer Institute2023-01-302024-01-23
Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Biopsy, Calaspargase Pegol-mknl, Cobimetinib - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Phase 1CompletedOHSU Knight Cancer Institute152022-08-092026-07-23
Cobimetinib In Extracranial Arteriovenous Malformations (COBI-AVM Study)
Cobimetinib - Arteriovenous Malformations (Extracranial)
Phase 2CompletedUniversity of Arkansas32022-07-262026-11-12
Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US
Encorafenib, Binimetinib, Vemurafenib - Melanoma
CompletedPfizer7162022-01-172025-03-06
Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
Atezolizumab, Biopsy, Biospecimen Collection - Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma
Phase 2Active not recruitingNational Cancer Institute (NCI)572021-12-152025-05-23
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Alectinib, Cobimetinib, Vismodegib - Advanced Cancer, Solid Tumor
Phase 2RecruitingHelsinki University Central Hospital2502021-12-102026-11-10
CRAFT: The NCT-PMO-1602 Phase II Trial
Vemurafenib, Cobimetinib, Atezolizumab - Metastatic or Locally Advanced Malignancies
Phase 2CompletedGerman Cancer Research Center722021-10-132025-01-08
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
Ipatasertib, Cobimetinib, Trastuzumab Emtansine - Ovarian Cancer
Phase 2Active not recruitingHoffmann-La Roche1762021-10-072026-09-10
Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study
Trametinib, Cobimetinib, Binimetinib - Cancer
Not applicableTerminatedPeter MacCallum Cancer Centre, Australia32021-09-232023-05-10
A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.
Belvarafenib, Cobimetinib, Nivolumab - Melanoma
Phase 1Active not recruitingGenentech, Inc.652021-05-132026-09-30
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
Cobimetinib - Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma
Phase 2RecruitingCarl Allen902021-04-192026-10-26
Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations
Cobimetinib - Chronic Myelomonocytic Leukemia (CMML)
Phase 2Active not recruitingUniversity of Utah142021-01-122026-10-26

Showing 20 of 112. Sign in to see all of them.

Conditions studied

Melanoma (34)  ·  Neoplasms (14)  ·  Carcinoma, Non-Small-Cell Lung (10)  ·  Colorectal Neoplasms (8)  ·  Ovarian Neoplasms (7)  ·  Breast Neoplasms (6)  ·  Multiple Myeloma (6)  ·  Pancreatic Neoplasms (5)  ·  Hematologic Neoplasms (4)  ·  Neoplasm Metastasis (4)  ·  Brain Neoplasms (3)  ·  Cholangiocarcinoma (3)  ·  Gastrointestinal Neoplasms (3)  ·  Leukemia, Myeloid, Acute (3)  ·  Lung Neoplasms (3)

Sponsors

Hoffmann-La Roche (26)  ·  Genentech, Inc. (16)  ·  M.D. Anderson Cancer Center (4)  ·  National Cancer Institute (NCI) (4)  ·  OHSU Knight Cancer Institute (4)  ·  Fondazione Melanoma Onlus (3)  ·  Bristol-Myers Squibb (2)  ·  Cancer Research UK (2)  ·  City of Hope Medical Center (2)  ·  Hanmi Pharmaceutical Company Limited (2)  ·  Peter MacCallum Cancer Centre, Australia (2)  ·  ABM Therapeutics Corporation (1)  ·  Alliance for Clinical Trials in Oncology (1)  ·  American Society of Clinical Oncology (1)  ·  Assistance Publique - Hôpitaux de Paris (1)

Countries

United States (74)  ·  Spain (24)  ·  France (21)  ·  Germany (20)  ·  Italy (20)  ·  Australia (19)  ·  South Korea (18)  ·  United Kingdom (16)  ·  Canada (13)  ·  Belgium (11)  ·  Netherlands (9)  ·  Poland (9)  ·  Brazil (8)  ·  Israel (8)  ·  Russia (8)

Top investigators

Isabelle Rooney, M.D., PhD (3)  ·  Charles D Lopez (2)  ·  Matthew Krebs, Dr (2)  ·  Michael B Atkins, MD (2)  ·  Mohammed Milhem, MD (2)  ·  Nilofer S Azad (2)  ·  Alfonso Berrocal, MD, PhD (1)  ·  Ami Patel, MD (1)  ·  Andrea Botticelli (1)  ·  Anna Pavlick, MD (1)  ·  Brian Ball (1)  ·  Carl E Allen, MD, PhD (1)  ·  Claus Garbe, Prof. (1)

Results publications

PMID 36310331, PMID 33476492, PMID 32746839, PMID 36648215, PMID 36940261, PMID 22651703, PMID 24577748, PMID 25037139, PMID 25265494, PMID 27269741, PMID 27480103, PMID 27733243, PMID 28444112, PMID 28592615, PMID 28646893, PMID 28734759, PMID 28915798, PMID 29320312, PMID 29355075, PMID 29489427, PMID 30110194, PMID 30857956, PMID 30918950, PMID 31003911, PMID 31100038, PMID 31171876, PMID 32086697, PMID 32534646, PMID 32737717, PMID 33068284, PMID 33090333, PMID 33407577, PMID 33720068, PMID 33844595, PMID 34158360, PMID 34339623, PMID 34637336, PMID 34808524, PMID 34825282, PMID 34853302, PMID 34876409, PMID 34907910, PMID 35086719, PMID 35131452, PMID 35587446, PMID 35598186, PMID 35649212, PMID 35715627, PMID 35940183, PMID 35995953

NIH funding

2016 (8), 2017 (6), 2014 (5), 2015 (3), 2018 (3), UM1CA186691 (3), P30CA033572 (2), 2023 (1), U10CA180821 (1), UM1CA186709 (1)